<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEUCOVORIN CALCIUMÂ - leucovorin calciumÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Leucovorin Calcium Tablets USP contain either 5 mg, 10 mg, 15 mg 
or 25 mg leucovorin as the calcium salt of 
N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl] 
amino]benzoyl]-L-glutamic acid. This is equivalent to either 5.40 mg, 10.80 mg, 
16.21 mg or 27.01 mg of anhydrous leucovorin calcium, respectively. In addition, 
each tablet contains the following <span class="Italics">inactive 
ingredients</span>: microcrystalline cellulose, corn starch, croscarmellose 
sodium, povidone, colloidal silicon dioxide, magnesium stearate, D&amp;C yellow 
#10 (15mg and 25 mg).</p>
<p>Leucovorin is a water soluble form of reduced folate in the folate group; it 
is useful as an antidote to drugs which act as folic acid antagonists. These 
tablets are intended for oral administration only.</p>
<p>The structural formula of leucovorin calcium is:</p>
<div class="Figure"><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=084227c1-90eb-4653-807a-eb98cb3cefb8&amp;name=chemical%20structure.jpg"></div>
<p>C<span class="Sub">20</span>H<span class="Sub">21</span>CaN<span class="Sub">7</span>O<span class="Sub">7</span> M.W. 511.51</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Leucovorin is a racemic mixture of the diastereoisomers of the 
5-formyl derivative of tetrahydrofolic acid. The biologically active compound of 
the mixture is the (-)-L-isomer, known as <span class="Italics">Citrovorum 
factor</span>, or (-)-folinic acid. Leucovorin does <span class="Italics">not</span> require reduction by the enzyme dihydrofolate reductase 
in order to participate in reactions utilizing folates as a source of 
â€œone-carbonâ€? moieties. Following oral administration, leucovorin is rapidly 
absorbed and enters the general body pool of reduced folates. The increase in 
plasma and serum folate activity (determined microbiologically with <span class="Italics">Lactobacillus casei</span> ) seen after oral administration of 
leucovorin is predominantly due to 5-methyltetrahydrofolate.</p>
<p>Twenty normal men were given a single, oral 15 mg dose (7.5 mg/m<span class="Sup">2</span>) of leucovorin calcium and serum folate concentrations were 
assayed with <span class="Italics">L. casei</span>. Mean values observed (Â± one 
standard error) were:</p>
<p>a) Time to peak serum folate concentration: 1.72 Â± 0.08 hours,</p>
<p>b) Peak serum folate concentration achieved: 268 Â± 18 ng/mL,</p>
<p>c) Serum folate half-disappearance time: 3.5 hours.</p>
<p>Oral tablets yielded areas under the serum folate concentration-time curves 
(AUCs) that were 12% greater than equal amounts of leucovorin given 
intramuscularly and equal to the same amounts given intravenously.</p>
<p>Oral absorption of leucovorin is saturable at doses above 25 mg. The apparent 
bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 
mg.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Leucovorin Calcium Tablets USP are indicated to diminish the toxicity and 
counteract the effects of impaired methotrexate elimination and of inadvertent 
overdosages of folic acid antagonists.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Leucovorin is improper therapy for <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> and other megaloblastic 
<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> secondary to the lack of vitamin B<span class="Sub">12</span>. A 
hematologic remission may occur while neurologic manifestations continue to 
progress.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the treatment of accidental overdosage of folic acid 
antagonists, leucovorin should be administered as promptly as possible. As the 
time interval between antifolate administration (e.g., methotrexate) and 
leucovorin rescue increases, leucovorinâ€™s effectiveness in counteracting 
hematologic toxicity decreases.</p>
<p>Monitoring of the serum methotrexate concentration is essential in 
determining the optimal dose and duration of treatment with leucovorin.</p>
<p>Delayed methotrexate excretion may be caused by a third space fluid 
accumulation (i.e., <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or 
inadequate hydration. Under such circumstances, higher doses of leucovorin or 
prolonged administration may be indicated. Doses higher than those recommended 
for oral use must be given intravenously.</p>
<p>Leucovorin may enhance the toxicity of fluorouracil. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from severe 
<span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been reported in elderly patients 
receiving weekly leucovorin and fluorouracil.<span class="Sup">1</span> 
Concomitant <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> were present in some but not all of the 
patients.</p>
<p>The concomitant use of leucovorin with trimethoprim-sulfamethoxazole for the 
acute treatment of <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in 
patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> was associated with increased rates of treatment 
failure and mortality in a placebo-controlled study.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<p class="First">Parenteral administration is preferable to oral dosing if there 
is a possibility that the patient may vomit or not absorb the leucovorin. 
Leucovorin has no effect on other established toxicities of methotrexate such as 
the <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> resulting from drug and/or metabolite precipitation in the 
kidney.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>Folic acid in large amounts may counteract the antiepileptic 
effect of phenobarbital, phenytoin and primidone, and increase the frequency of 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in susceptible children.</p>
<p>Preliminary animal and human studies have shown that small quantities of 
systemically administered leucovorin enter the CSF primarily as 
5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower 
than the usual methotrexate concentrations following intrathecal administration. 
However, high doses of leucovorin may reduce the efficacy of intrathecally 
administered methotrexate.</p>
<p>Leucovorin may enhance the toxicity of fluorouracil (see <a href="#section-7">WARNINGS</a>). </p>
<a href="http://"></a><a href="http://"></a>Pregnancy:<p><span class="Italics">Teratogenic Effects:</span> Pregnancy 
Category C</p>
<p>Animal reproduction studies have not been conducted with leucovorin. It is 
also not known whether leucovorin can cause fetal harm when administered to a 
pregnant woman or can affect reproduction capacity. Leucovorin should be given 
to a pregnant woman only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>It is not known whether this drug is excreted in human milk. 
Because many drugs are excreted in human milk, caution should be exercised when 
leucovorin is administered to a nursing mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>See <a href="#section-8.2">Drug Interactions</a> subsection.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Allergic sensitization, including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, has 
been reported following the administration of both oral and parenteral 
leucovorin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Excessive amounts of leucovorin may nullify the chemotherapeutic effect of folic 
acid antagonists.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Leucovorin calcium tablets are intended for oral administration. 
Because absorption is saturable, oral administration of doses greater than 25 mg 
is not recommended.</p>
<a href="http://"></a><a href="http://"></a>Impaired Methotrexate Elimination or Inadvertent 
Overdosage<p>Leucovorin rescue should begin as soon as possible after an 
inadvertent overdosage and within 24 hours of methotrexate administration when 
there is delayed excretion (see <a href="#section-7">WARNINGS</a>). Leucovorin 
15 mg (10 mg/m<span class="Sup">2</span>) should be administered IM, IV, or PO 
every 6 hours until the serum methotrexate level is less than 10<span class="Sup">-8</span> M. In the presence of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or 
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, leucovorin should be administered parenterally.</p>
<p>Serum creatinine and methotrexate levels should be determined at 24-hour 
intervals. If the 24-hour serum creatinine has increased 50% over baseline or if 
the 24-hour methotrexate level is greater than 5 x 10<span class="Sup">-6</span> M 
or the 48-hour level is greater than 9 x 10<span class="Sup">-7</span> M, the dose 
of leucovorin should be increased to 150 mg (100 mg/m<span class="Sup">2</span>) 
IV every 3 hours until the methotrexate level is less than 10<span class="Sup">-8 
</span>M. Doses greater than 25 mg should be given parenterally (see <a href="#section-4">CLINICAL PHARMACOLOGY</a>).</p>
<p>Hydration (3 L/d) and urinary alkalinization with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should 
be employed concomitantly. The <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> dose should be adjusted to maintain 
the urine pH at 7.0 or greater.</p>
<p>The recommended dose of leucovorin to counteract hematologic toxicity from 
folic acid antagonists with less affinity for mammalian dihydrofolate reductase 
than methotrexate (i.e., trimethoprim, pyrimethamine) is substantially less, and 
5 to 15 mg of leucovorin per day has been recommended by some investigators.</p>
<p>Patients who experience delayed early methotrexate elimination are likely to 
develop reversible non-oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. In addition to appropriate 
leucovorin therapy, these patients require continuing hydration and urinary 
alkalinization, and close monitoring of fluid and electrolyte status, until the 
serum methotrexate level has fallen below 0.05 micromolar and the <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> 
has resolved.</p>
<p>Some patients will have abnormalities in methotrexate elimination or renal 
function following methotrexate administration, which are significant but less 
severe. These abnormalities may or may not be associated with significant 
clinical toxicity. If significant clinical toxicity is observed, leucovorin 
rescue should be extended for an additional 24 hours (total 14 doses over 84 
hours) in subsequent courses of therapy. The possibility that the patient is 
taking other medications which interact with methotrexate (e.g., medications 
which may interfere with methotrexate elimination or binding to serum albumin) 
should always be reconsidered when laboratory abnormalities or clinical 
toxicities are observed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Leucovorin Calcium Tablets USP are available for oral 
administration as:</p>
<p><span class="Bold">5 mg white, scored tablets (Identified 54 293).</span></p>
<a name="i333ddae8-6498-4239-86e1-6a53eeb53bdf"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>NDC 54868-3310-3<br>
</td>
<td>Bottles of 2<br>
</td>
</tr>
<tr>
<td>NDC 54868-3310-4<br>
</td>
<td>Bottles of 4<br>
</td>
</tr>
<tr>
<td>NDC 54868-3310-2<br>
</td>
<td>Bottles of 10<br>
</td>
</tr>
<tr>
<td>NDC 54868-3310-1<br>
</td>
<td>Bottles of 50<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-3310-0<br>
</td>
<td>Bottles of 60<br>
</td>
</tr>
</tbody></table>
<span class="Bold"><br>15 mg yellow, scored tablets (Identified 54 650).</span><a name="i149da50f-cd72-46df-8d83-39e40dc8d11b"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>NDC 54868-5915-0<br>
</td>
<td>Bottles of 24<br>
</td>
</tr></tbody></table>
<p></p>Store at Controlled Room Temperature 15Â°-30Â°C (59Â°-86Â°F).<p><span class="Bold">Protect From Light and Moisture.</span></p>
<p><br><span class="Bold"></span></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>References:</h1>
<ol>
<li>Grem JL, Shoemaker DD, Petrelli NJ, Douglas HO. Severe and fatal toxic 
effects observed in treatment with high- and low-dose leucovorin plus 
5-fluorouracil for colorectal carcinoma. <span class="Italics">Cancer Treat 
Rep</span> 1987;71:1122.</li>
<li>Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on 
relapse-free survival in patients with <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> of the extremity. <span class="Italics">N Engl J Med</span> 1986;314:1600-1606.</li>
</ol>
<p class="First"><span class="Bold">4055309//02pc120</span></p>
<p>Â© RLI, 2000</p>
<p><img alt="image of Roxane logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=084227c1-90eb-4653-807a-eb98cb3cefb8&amp;name=Roxane%20logo.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Leucovorin Calcium Tablets USP <br></p>
<p>5 mg</p>
<div class="Figure"><img alt="image of 5 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=084227c1-90eb-4653-807a-eb98cb3cefb8&amp;name=5mg%20package%20label.jpg"></div>
<p><br></p>
<p>15 mg</p>
<p><img alt="image of 15 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=084227c1-90eb-4653-807a-eb98cb3cefb8&amp;name=15mg%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEUCOVORIN CALCIUMÂ 		
					</strong><br><span class="contentTableReg">leucovorin calcium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3310(NDC:0054-4496)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEUCOVORIN CALCIUM</strong> (LEUCOVORIN) </td>
<td class="formItem">LEUCOVORIN CALCIUM</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;293</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3310-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3310-1</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-3310-2</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-3310-3</td>
<td class="formItem">2  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-3310-4</td>
<td class="formItem">4  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072733</td>
<td class="formItem">04/15/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEUCOVORIN CALCIUMÂ 		
					</strong><br><span class="contentTableReg">leucovorin calcium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5915(NDC:0054-8498)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEUCOVORIN CALCIUM</strong> (LEUCOVORIN) </td>
<td class="formItem">LEUCOVORIN CALCIUM</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;650</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5915-0</td>
<td class="formItem">24  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072735</td>
<td class="formItem">07/08/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d67caab0-2ebd-4d80-a415-2e329fb5a34e</div>
<div>Set id: 084227c1-90eb-4653-807a-eb98cb3cefb8</div>
<div>Version: 2</div>
<div>Effective Time: 20100602</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
